Bharat Biotech joins global efforts in developing coronavirus vaccine

CoroFlu will build on the backbone of vaccine firm FluGen's flu vaccine candidate, a self-limiting version of the influenza virus that induces an immune response against the flu.

Hyderabad-based vaccine maker Bharat Biotech said today that it was a part of an international collaboration of virologists and vaccine companies that has begun working on the development and testing CoroFlu, of a unique intranasal vaccine against Covid-19.

CoroFlu will build on the backbone of vaccine company FluGen's flu vaccine candidate known as M2SR, which  is a self-limiting version of the influenza virus that induces an immune response against the flu. FluGen's lab will insert gene sequences from SARS-CoV-2, the coronavirus that causes Covid-10, into M2SR sot that the new vaccine will also induce immunity against the pathogen.

Sharing the